PHILADELPHIA and VANCOUVER, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces today that the Company will be conducting two virtual investor presentations on Thursday, June 12, at 12:00 PM EDT and on Thursday, June 26, at 12:00 PM EDT, arranged by Renmark Financial Communications Inc. Briacell Therape ...

PHILADELPHIA and VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced underwritten public offering of 3,066,666 units, including 399,999 units sold upon the full exercise of the underwriter’s option to purchase additional units. Each unit consists of o ...

Core Points - BriaCell Therapeutics Corp. announced a public offering of 3,066,666 units at a price of $4.50 per unit, aiming for gross proceeds of approximately $13.8 million [1][2] - Each unit consists of one common share (or Pre-Funded Warrant) and one Warrant, with the Warrants approved for listing on the Nasdaq Capital Market under the symbol "BCTXZ" [1] - The offering is expected to close on April 28, 2025, subject to customary closing conditions [2] - The net proceeds will be used for working capital, general corporate purposes, and advancing business objectives [3] - A registration statement related to the securities was filed with the SEC and became effective on April 24, 2025 [4] Company Information - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care [6]